Identification of Marker Genes for Predicting the Osteogenic Differentiation Potential of Mesenchymal Stromal Cells

by Masami Kanawa

Submission date: 16-Apr-2022 08:10PM (UTC+0800)

Submission ID: 1812011108

File name: genic_Differentiation_Potential_of_Mesenchymal_Stromal_Cells.pdf (983.6K)

Word count: 4741

Character count: 25269





Type of the Paper (Articl)

10

Identification of marker genes for predicting the osteogenic differentiation

potential of mesenchymal stromal cells

Masami Kanawa ¹, Akira Igarashi ^{2,3}, Katsumi Fujimoto ^{3,4}, Tania Saskianti ^{3,5}, Ayumu Nakashima ⁶, Yukihito Higashi ⁷, Hidemi Kurihara ⁸, Yukio Kato ³ and Takeshi Kawamoto ^{3,9*}

5

10

12

13

14 15

16

17

18

22

24

25

26

27

28

29

30

31

32

33

34

35

36

37

38

4

- Natural Science Center for Basic Research and Development, Hiroshima University, Hiroshima, 734-8533, Japan.
- ² Division of Advanced Technology and Development, BML, Inc., Saitama, 350-1101, Japan.
- Department of Dental and Medical Biochemistry, Graduate School of Biomedical & Health Sciences, Hiroshima University, Hiroshima, 734-8533, Japan; yyykka@hotmail.co.jp (Y.K)
- Department of Molecular Biology and Biochemistry, Graduate School of Biomedical & Health Sciences, Hiroshima University, Hiroshima, 734-8533, Japan.
- Department of Pediatric Dentistry, Faculty of Dental Medicine, Universitas Airlangga, 60132, Indonesia.
- ⁶ Department of Stem Cell Biology and Medicine, Hiroshima University Graduate School of Biomedical Sciences, Hiroshima, 734-8533, Japan.
- Research Center for Radiation Genome Medicine, Research Institute for Radiation Biology and Medicine, Hiroshima University; Hiroshima, 734-8533, Japan.
- Bepartments of Periodontal Medicine, Graduate School of Biomedical & Health Sciences, Hiroshima University, Hiroshima, 734-8533, Japan.
- 9 Writing Center, Hiroshima University, Higashi-Hiroshima 739-8512, Japan.
- * Correspondence: tkawamo@hiroshima-u.ac.jp; Tel.: +81-82-424-6207

19 20 21

Abstract: Mesenchymal stromal cells (MSCs) have the potential to differentiate into a variety of mature cell types and are a promising source of regenerative medicine. The success of regenerative medicine using MSCs strongly depends on their differentiation potential. In this study, we sought to identify marker genes for predicting the osteogenic differentiation potential by comparing ilium MSC and fibroblast samples. We measured the mRNA levels of 95 candidate genes in nine ilium MSC and four fibroblast samples before osteogenic induction, and compared them with alkaline phosphatase (ALP) activity as a marker of osteogenic differentiation after induction. We identified 17 genes whose mRNA expression levels positively correlated with ALP activity. Next, we compared the mRNA levels of the 17 genes in ilium MSCs with those in jaw MSCs, which have different differentiation properties. The levels of seven out of the 17 genes were not substantially different between jaw and ilium MSCs, while the remaining 10 genes were expressed at significantly lower levels in jaw MSCs than in ilium MSCs. The mRNA levels of the seven similarly expressed genes were also compared with those in fibroblasts, which have little or no osteogenic differentiation potential. Among the seven genes, the mRNA levels of IGF1 and SRGN in all MSCs examined were higher than those in any of the fibroblasts. These results suggest that measuring the mRNA levels of IGF1 and SRGN before osteogenic induction will provide useful information for selecting competent MSCs for regenerative medicine.

Keywords: Mesenchymal stromal cell; osteogenesis; fibroblast; predictive marker gene; ALP activity;

44

45

46

47

48

49

50

51

52

53

54

55

56

57

58

59

60

61

62

63

64

65

66

67

68

69

70

71

72

73

74

75

76

77

78

79

80

81

82

83

84

85

86

87

88

89

90

1. Introduction 42

Mesenchymal stromal cells (MSCs) are multipotent precursor cells that differentiate into mature cells such as osteocytes, adipocytes, chondrocytes, neurocytes, and cardiomyocytes [1] [2] [3]. Previous studies have reported the use of MSCs in regenerative medicine and tissue engineering [4]; in particular, MSCs are applicable to clinical practice for a wide range of bone diseases, including osteoporosis, osteonecrosis, and fracture by trauma [5] [6]. [7] [8].

MSCs obtained from different tissues have differing differentiation abilities. For example, bone marrow-derived MSCs exhibit a higher osteogenic differentiation potential than adipose-derived MSCs [9]. In contrast, the adipogenic differentiation potential of adipose-derived MSCs is higher than that of bone marrow-derived MSCs, while MSCs derived from the synovium have a higher chondrogenic differentiation potential than bone marrow-derived MSCs [10]. Thus, MSCs obtained from different tissues seem to have intrinsic differentiation abilities related to their origin.

Herrmann et al. [11] reported that the chondrogenic differentiation potential of ilium MSCs was superior to that of tibia MSCs, although their osteogenic differentiation potentials were similar. In contrast, the chondrogenic and adipogenic differentiation potentials of jaw MSCs were lower than those of ilium MSCs, but the osteogenic differentiation potential of jaw MSCs was comparable to that of ilium MSCs [12] [13]. Therefore, as the specific differentiation ability of MSCs depends on their source, it is highly desirable to assess the differentiation potential of MSCs before their clinical application.

Recent studies have shown that surface antigens and specific genes expressed in undifferentiated MSCs before differentiation induction can serve as markers to predict their differentiation potential. For example, the CD271, CD146, and CD105 surface antigens have been reported as predictive markers of chondrogenic differentiation [14] [15] [16]. More recently, we identified predictive marker genes for chondrogenic and adipogenic differentiation of MSCs by taking advantage of the difference in differentiation abilities between ilium and jaw MSCs [17] [18]. However, we could not identify predictive markers for their osteogenic differentiation potential by using the difference between ilium and jaw MSCs because there was no difference. Although WNT16, the osteogenic differentiation predictive gene marker for tonsil-derived MSCs, was identified by Kim et al. [19], osteogenic differentiation predictive marker genes for bone marrow-derived MSCs have not yet been reported.

Fibroblasts are very similar to MSCs in terms of their origin and morphology [20]. Because there is little or no difference in the expression patterns of surface antigens between fibroblasts and MSCs, it is difficult to distinguish between these two cell types by assessing surface antigens [20]. However, Igarashi et al. [13]successfully identified MSC marker genes that can distinguish between fibroblasts and MSCs by using differences in gene expression profiles between these cells. Of the 95 candidate genes selected with DNA microarrays, nine were identified as MSC markers using the real-time quantitative polymerase chain reaction (RT-qPCR) for ilium, jaw, tibia, and femur MSCs, as well as fibroblasts. It has long been believed that fibroblasts have no differentiation potential [1]; however, Chen et al. [21] and Haniffa et al. [22] have recently reported that induced fibroblasts exhibit adipogenic, osteogenic, or chondrogenic differentiation phenotypes. Moreover, Fleury, et al. [23] found low, but significant, alkaline phosphatase (ALP) activity as an osteogenic differentiation marker after induction of fibroblasts. These findings suggest that osteogenic differentiation predictive markers can be identified by comparing osteogenic differentiation markers, such as ALP activity, with gene expression levels in fibroblasts and MSCs.

Citation: Lastname, F.; Lastname, F.; Lastname, F. Title. Int. J. Mol. Sci. 2021, 22, x. https://doi.org/10.3390/xxxxx

Academic Editor: Firstname Lastname

Received: date Accepted: date Published: date

Publisher's Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.



Copyright: © 2021 by the authors. Submitted for possible open access publication under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).

In this study, we sought to identify predictive markers of osteogenic differentiation for the selection of competent MSCs. Osteogenic differentiation was induced in nine ilium MSC samples and four fibroblast samples using osteogenic induction medium, and ALP activity was measured. We investigated the correlation between ALP activity in the 13 cell samples and the expression levels of 95 genes before induction. The results showed that there was a significant correlation between the expression levels of 17 genes and ALP activity. These genes can function as osteogenic predictive markers for the clinical application of MSCs.

2. Results

2.1 Selection of candidate genes for osteogenic predictive markers

To identify candidates for osteogenic differentiation predictive markers, we examined the correlation between gene expression levels before osteogenic induction of MSCs and the extent of MSC differentiation after induction. First, we measured the mRNA expression levels of 95 candidate genes in nine MSC and four fibroblast samples before induction (Table S1). After inducing osteogenic differentiation of these cells, we evaluated ALP activity on day 14 as an osteogenic differentiation marker. Correlation coefficients between the mRNA levels before induction and ALP activity after induction in the 13 cell samples were calculated. The results indicated that 17 out of 95 genes showed a significant positive correlation with ALP activity (Table 1). Thus, we identified 17 candidate predictive marker genes for the osteogenic potential of MSCs.

Table 1. Osteogenic predictive marker genes that are significantly positively correlated with ALP activity after osteogenic induction

Gene	Full name	r
MCAM	melanoma cell adhesion molecule	0.889**
DNCI1	dynein cytoplasmic 1 intermediate chain 1	0.824**
HGF	hepatocyte growth factor	0.813**
HLA-DRA	major histocompatibility complex, class II, DR alpha	0.780**
HLA-DRB	major histocompatibility complex, class II, DR beta	0.762**
SRGN	serglycin	0.727**
SERPINI1	serpin family E member 1	0.724**
ACLY	ATP citrate lyase	0.705**
P4HA2	prolyl 4-hydroxylase subunit alpha 2	0.669*
ITGA5	integrin subunit alpha5	0.648*
TFPI2	tissue factor pathway inhibitor 2	0.620*
KCTD12	potassium channel tetramerization domain containing 12	0.617*
LIF	leukemia inhibitory factor	0.614*
PSMC5	proteasome 26S Subunit, ATPase 5	0.589*
CD74	CD74 molecule	0.585*
TRIB2	tribbles pseudokinase 2	0.579*
IGF1	insulin like growth factor 1	0.560*

r: Pearson correlation coefficient; *P < 0.05, **P < 0.01



119

120

121

122

123

124

125

126

127

128

129

130

131

132

133

134

2.2 Comparison of expression levels of candidate genes for osteogenic predictive markers among three different cell sources

Previous studies have shown that the chondrogenic and adipogenic differentiation potentials of jaw MSCs are lower than those of ilium MSCs, but the osteogenic differentiation potential of jaw MSCs is comparable with that of ilium MSCs [12] [13]. Therefore, osteogenic differentiation predictive markers are expected to be expressed in jaw and ilium MSCs at similar levels. In addition, marker genes should be expressed at much lower levels in fibroblasts. We compared mRNA levels of the 17 candidate genes among the ilium and jaw MSCs, and fibroblasts (Figure 1). The mRNA expression levels of HGF, IGF, KCTD12, TRIB2, SRGN, and TFPI2 in jaw MSCs were similar to those in ilium MSCs. The mRNA level of SERPINI1 in jaw MSCs was higher than that in ilium MSCs. In contrast, the expression levels of CD74, LIF, ITGA5, ACLY, DNCI1, MCAM, HLA-DRA, HLA-DRB, and P4HA2 in jaw MSCs were much lower than those in ilium $MSCs.\ Together,\ these\ results\ suggest\ that\ the\ seven\ genes,\ HGF,\ IGF,\ KCTD12,\ TRIB2,$ SRGN, TFPI2, and SERPINI1, can serve as osteogenic differentiation predictive markers. Importantly, the expression levels of these seven genes in both MSCs were much higher than those in fibroblasts, though the expression level of PSMC5 was not different among ilium MSCs, jaw MSCs, and fibroblasts.






Figure 1. Comparison of osteogenic differentiation predictive markers among ilium mesenchymal stromal cells (MSCs) (n = 9), jaw MSCs (n = 5), and fibroblasts (FBs) (n = 4). mRNA levels of 11 marker genes were quantified before differentiation induction. The significance of differences between groups was analyzed by the Mann-Whitney U-test (* p < 0.05;** p < 0.01; *** p < 0.001; n.s., not significant). Data are shown as means ± SEM.



2.3 Comparison of expresson levels of osteogenic predictive markers in individual MSCs and fibroblasts

Effective osteogenic differentiation predictive markers should be able to distinguish between fibroblasts and MSCs. To compare the expression levels of the seven osteogenic differentiation predictive marker genes among individual fibroblasts and MSCs, we analyzed their expression profiles in four individual fibroblast and nine individual MSC samples using scatter plots (Fig. 2). The mRNA levels of *IGF1* and *SRGN* in all MSCs were higher than those in any of the examined fibroblasts. Namely, the minimum IGF1 mRNA level in nine MSC samples was 221 times higher than the maximum value of those in the four fibroblast samples. Likewise, the minimum value of *SRGN* mRNA in the nine MSC samples was 12.5 times higher than the maximum value in the four fibroblast samples. Although the minimum value of *TRIB2* mRNA in the nine MSC samples was higher than the maximum value in the four fibroblast samples, the difference between them was marginal (1.1 times). Regarding *HGF*, *KCTD12*, *SERPIN11*, and *TFP12*, the minimum mRNA values in the nine MSC samples were lower than the maximum values in the four fibroblast samples. Together, these results suggest that *IGF1* and *SRGN* are particularly potent osteogenic differentiation predictive markers.

165

166




Figure 2. Analysis of mRNA levels of osteogenic differentiation predictive markers in individual fibroblasts (FBs) and ilium mesenchymal stromal cells (MSCs). The horizontal bars represent the mean value for each group.

2.4. Comparison of differentiation predictive markers in three MSC lineages

Using a Venn diagram, we classified the 17 markers identified here together with eight chondrogenic and 11 adipogenic predictive markers reported in our previous studies. Among the 17 markers, ACLY, CD74, and LIF were identified as osteogenic, adipogenic, and chondrogenic predictive markers. In addition, MCAM, DNC11, ITGA5, and P4HA2 were recognized as osteogenic and adipogenic predictive markers, but not as chondrogenic predictive markers. The remaining 10 genes, HGF, SRGN, SERPINI1, TFP12, KCTD12, TRIB2, IGF1, HLA-DRA, HLA-DRB, and PSMC5, may serve only as osteogenic predictive markers. Thus, the 17 markers could be classified into three groups.




Figure 3. Classification of differentiation predictive marker genes for mesenchymal stromal cells into three lineages of osteogenic, adipogenic [18], and chondrogenic [17] differentiation.

3. Discussion 183

In this study, we screened for osteogenic differentiation predictive markers of MSCs. The expression levels of 95 candidate genes in ilium bone marrow-derived MSCs and fibroblasts were compared with ALP activity as the differentiation marker. Of the 95 genes, the expression profiles of 17 correlated significantly with ALP activity. By comparing the mRNA levels of the 17 genes in jaw and ilium MSCs, we excluded 10 genes that showed much lower expression in jaw MSCs than in ilium MSCs. Thus, we identified seven genes as predictive markers for osteogenic differentiation. Among these seven genes, the mRNA levels of *IGF1* and *SRGN* in all MSCs were higher than those in any

fibroblasts used in this study. Thus, these two genes may serve as effective markers for MSCs for use in bone regenerative therapy.

It is well-known that *IGF1* plays an important role in bone formation by osteo-blasts [24]. Recently, Koch et al. [25] showed that transfection with an IGF1-expressing adenovirus induced osteogenic marker genes, including type I collagen, Runx2, and ALP genes, in MSCs. This suggests that MSCs expressing high levels of *IGF1* have a high osteogenic differentiation potential. Accordingly, our results demonstrate that mRNA levels of *IGF1* in undifferentiated MSCs can predict the degree of osteogenic differentiation after induction.

SRGN is a proteoglycan with a repeated structure of Ser-Gly dipeptides. [26]. Bae et al. [27] reported that the expression level of *SRGN* in MSCs was 33.8 times higher than that in fibroblasts. In this study, *SRGN* expression in ilium MSCs was 72.5 times higher than that in fibroblasts (Figure 1). In addition, Kristensen et al. [28] found that the protein levels of SRGN in the culture supernatant of MSCs increased at the beginning of osteogenic induction. These findings suggest that SRGN mRNA and protein are highly expressed in MSCs before osteogenic induction, and SRGN is involved in osteogenic differentiation.

For clinical applications of MSCs in regenerative medicine, it is important to use MSCs without fibroblast contamination. To distinguish between MSCs and fibroblasts, Igarashi et al. identified nine MSC marker genes. Six (*LIF*, *IGF1*, *SRGN*, *KCTD12*, *TRIB2*, and *DNCI1*) out of these nine MSC marker genes were included in the 17 genes identified in the present study. These results suggest that these six genes can serve not only as MSC markers, but also as osteogenic differentiation predictive markers.

As shown in Figure 3, the 17 osteogenic differentiation predictive markers identified in this study could be divided into three groups with different potentials: one lineage with osteogenic differentiation potential, two lineages with osteogenic and adipogenic differentiation potential, and three lineages with osteogenic, adipogenic, and chondrogenic differentiation potential. For bone-regenerative therapy, MSCs are not required to have the ability to differentiate into all three lineages. Therefore, excellent markers for predicting the osteogenic differentiation potential can be powerful tools.

4. Materials and Methods

4.1 Cells and Cell Culture

Bone marrow-derived MSCs and fibroblasts were obtained from patients admitted to Hiroshima University Hospital as described previously [13] [17]. Fibroblasts were also obtained from Kurabo Industries [13]. The passage numbers of MSC and fibroblast cultures were 3-5 and 6-11, respectively. The detailed protocol for MSC culture was described previously by Igarashi et al. [13]. All processes were performed after approval by the Ethics Committee of Hiroshima University (D-88-4). Written informed consent was obtained from all patients.

4.2 Osteogenic Differentiation

MSCs and fibroblasts were induced for osteogenic differentiation according to previous studies [13] [29]. Briefly, 3×10^3 cells per cm² were seeded at in a 24-well plate and grown until confluence. Confluent cells were maintained in osteogenic induction medium for 14 days. ALP activity of the induced cells was measured [30], and the values were normalized using DNA content.

4.3 RT-qPCR 239

n 235 e 236

2.

3.

7.

8.

RT-qPCR analysis of 95 candidate genes was performed using the ABI Prism 7900 240 Sequence Detection System with TaqMan (Applied Biosystems) as described previously. [13] mRNA expression levels were normalized to the mRNA level of β -action. The Taq-242 Man probe set IDs are listed Table S1. 243 244 4.4 Statistical analyses 245 All statistical analyses were performed using SPSS version 24. Pearson's correlation 246 coefficient was calculated to analyze the correlation between gene expression levels and 247 ALP activity. Gene expression levels among the three groups were evaluated using the 248 Mann-Whitney U test. 249 5. Conclusions 250 In this study, we identified two osteogenic differentiation predictive markers, SRGN 251 and IGF1. This makes it possible to evaluate the differentiation potential of MSCs in an 252 undifferentiated state. These two markers will facilitate tissue engineering for bone dis-253 eases, including osteoporosis, osteonecrosis, and fracture due to trauma. 254 Supplementary Materials: Table S1: Correlation between gene expression levels before osteogenic 255 induction and ALP activity after induction of four fibroblast and nine MSC samples. 256 Author Contributions: Conceptualization, M.K., Y.K., and T.K.; methodology, M.K., A.I., K.F., T.S., 257 A.N., Y.H., and H.K..; formal analysis, M.K. and A.I.; investigation, M.K., A.I., and T.S.; resources, 258 Y.H., and H.K.; writing—original draft preparation, M.K. and T.K.; writing—review and editing, 259 K.F., A.N., and Y.K.; visualization, M.F., A.I., and T.K.; supervision, H.K., Y.K., and T.K.; funding 260 acquisition, M.K. All authors have read and agreed to the published version of the manuscript. 261 Funding: This study was supported by JSPS KAKENHI (JP17K11541). 262 Informed Consent Statement: Written informed consent was obtained from all patients. 263 Data Availability Statement: The original data in this study are available on request. 264 Conflicts of Interest: The authors declare no potential conflicts of interest.s 265 References 266 267 Pittenger, M. F.; Mackay, A. M.; Beck, S. C.; Jaiswal, R. K.; Douglas, R.; Mosca, J. D.; Moorman, M. A.; Simonetti, D. W.; 268 Craig, S.; Marshak, D. R., Multilineage potential of adult human mesenchymal stem cells. Science 1999, 284, (5411), 143-7. 269 Bae, K. S.; Park, J. B.; Kim, H. S.; Kim, D. S.; Park, D. J.; Kang, S. J., Neuron-like differentiation of bone marrow-derived 270 271 mesenchymal stem cells. Yonsei Med J 2011, 52, (3), 401-12. Reger, R. L.; Tucker, A. H.; Wolfe, M. R., Differentiation and characterization of human MSCs. Methods Mol Biol 2008, 449, 272 93-107. 273 Han, Y.; Li, X.; Zhang, Y.; Han, Y.; Chang, F.; Ding, J., Mesenchymal Stem Cells for Regenerative Medicine. Cells 2019, 8, (8). 274 Kitoh, H.; Kawasumi, M.; Kaneko, H.; Ishiguro, N., Differential effects of culture-expanded bone marrow cells on the regeneration of bone between the femoral and the tibial lengthenings. J Pediatr Orthop 2009, 29, (6), 643-9. 276 Zhao, D.; Cui, D.; Wang, B.; Tian, F.; Guo, L.; Yang, L.; Liu, B.; Yu, X., Treatment of early stage osteonecrosis of the femoral 277 head with autologous implantation of bone marrow-derived and cultured mesenchymal stem cells. Bone 2012, 50, (1), 325-278 279 Hu, L.; Yin, C.; Zhao, F.; Ali, A.; Ma, J.; Qian, A., Mesenchymal Stem Cells: Cell Fate Decision to Osteoblast or Adipocyte 280 and Application in Osteoporosis Treatment. Int J Mol Sci 2018, 19, (2). 281 Iaquinta, M. R.; Mazzoni, E.; Bononi, I.; Rotondo, J. C.; Mazziotta, C.; Montesi, M.; Sprio, S.; Tampieri, A.; Tognon, M.; 282 Martini, F., Adult Stem Cells for Bone Regeneration and Repair. Front Cell Dev Biol 2019, 7, 268. 283

9.	Xu, L.; Liu, Y.; Sun, Y.; Wang, B.; Xiong, Y.; Lin, W.; Wei, Q.; Wang, H.; He, W.; Wang, B.; Li, G., Tissue source determines	284
	the differentiation potentials of mesenchymal stem cells: a comparative study of human mesenchymal stem cells from bone	285
	marrow and adipose tissue. Stem Cell Res Ther 2017, 8, (1), 275.	286
10.	Bearden, R. N.; Huggins, S. S.; Cummings, K. J.; Smith, R.; Gregory, C. A.; Saunders, W. B., In-vitro characterization of canine	287
	multipotent stromal cells isolated from synovium, bone marrow, and adipose tissue: a donor-matched comparative study.	288
	Stem Cell Res Ther 2017 , 8, (1), 218.	289
11.	Herrmann, M.; Hildebrand, M.; Menzel, U.; Fahy, N.; Alini, M.; Lang, S.; Benneker, L.; Verrier, S.; Stoddart, M. J.; Bara, J. J.,	290
	Phenotypic Characterization of Bone Marrow Mononuclear Cells and Derived Stromal Cell Populations from Human Iliac	291
	Crest, Vertebral Body and Femoral Head. Int J Mol Sci 2019, 20, (14).	292
12.	Matsubara, T.; Suardita, K.; Ishii, M.; Sugiyama, M.; Igarashi, A.; Oda, R.; Nishimura, M.; Saito, M.; Nakagawa, K.;	293
	Yamanaka, K.; Miyazaki, K.; Shimizu, M.; Bhawal, U. K.; Tsuji, K.; Nakamura, K.; Kato, Y., Alveolar bone marrow as a cell	294
	source for regenerative medicine: differences between alveolar and iliac bone marrow stromal cells. J Bone Miner Res 2005,	295
	20, (3), 399-409.	296
13.	Igarashi, A.; Segoshi, K.; Sakai, Y.; Pan, H.; Kanawa, M.; Higashi, Y.; Sugiyama, M.; Nakamura, K.; Kurihara, H.; Yamaguchi,	297
	S.; Tsuji, K.; Kawamoto, T.; Kato, Y., Selection of common markers for bone marrow stromal cells from various bones using	298
	real-time RT-PCR: effects of passage number and donor age. Tissue Eng 2007, 13, (10), 2405-17.	299
14.	Watson, J. T.; Foo, T.; Wu, J.; Moed, B. R.; Thorpe, M.; Schon, L.; Zhang, Z., CD271 as a marker for mesenchymal stem cells	300
	in bone marrow versus umbilical cord blood. Cells Tissues Organs 2013, 197, (6), 496-504.	301
15.	Hagmann, S.; Frank, S.; Gotterbarm, T.; Dreher, T.; Eckstein, V.; Moradi, B., Fluorescence activated enrichment of CD146+	302
	cells during expansion of human bone-marrow derived mesenchymal stromal cells augments proliferation and GAG/DNA	303
	content in chondrogenic media. BMC Musculoskelet Disord 2014, 15, 322.	304
16.	Fan, W.; Li, J.; Wang, Y.; Pan, J.; Li, S.; Zhu, L.; Guo, C.; Yan, Z., CD105 promotes chondrogenesis of synovium-derived	305
	mesenchymal stem cells through Smad2 signaling. Biochem Biophys Res Commun 2016, 474, (2), 338-344.	306
17.	Kanawa, M.; Igarashi, A.; Fujimoto, K.; Higashi, Y.; Kurihara, H.; Sugiyama, M.; Saskianti, T.; Kato, Y.; Kawamoto, T.,	307
	Genetic Markers Can Predict Chondrogenic Differentiation Potential in Bone Marrow-Derived Mesenchymal Stromal Cells.	308
	Stem Cells International 2018.	309
18.	Kanawa, M.; Igarashi, A.; Fujimoto, K.; Ronald, V. S.; Higashi, Y.; Kurihara, H.; Kato, Y.; Kawamoto, T., Potential Marker	310
	Genes for Predicting Adipogenic Differentiation of Mesenchymal Stromal Cells. Applied Sciences-Basel 2019, 9, (14).	311
19.	Kim, Y. H.; Cho, K. A.; Lee, H. J.; Park, M.; Kim, H. S.; Park, J. W.; Woo, S. Y.; Ryu, K. H., Identification of WNT16 as a	312
	Predictable Biomarker for Accelerated Osteogenic Differentiation of Tonsil-Derived Mesenchymal Stem Cells In Vitro. Stem	313
	Cells Int 2019, 2019, 8503148.	314
20.	Soundararajan, M.; Kannan, S., Fibroblasts and mesenchymal stem cells: Two sides of the same coin? J Cell Physiol 2018, 233,	315
	(12), 9099-9109.	316
21.	Chen, F. G.; Zhang, W. J.; Bi, D.; Liu, W.; Wei, X.; Chen, F. F.; Zhu, L.; Cui, L.; Cao, Y., Clonal analysis of nestin(-) vimentin(+)	317
	multipotent fibroblasts isolated from human dermis. J Cell Sci 2007, 120, (Pt 16), 2875-83.	318
22.	Haniffa, M. A.; Wang, X. N.; Holtick, U.; Rae, M.; Isaacs, J. D.; Dickinson, A. M.; Hilkens, C. M.; Collin, M. P., Adult human	319
	fibroblasts are potent immunoregulatory cells and functionally equivalent to mesenchymal stem cells. J Immunol 2007, 179,	320
	(3), 1595-604.	321
23.	Cappellesso-Fleury, S.; Puissant-Lubrano, B.; Apoil, P. A.; Titeux, M.; Winterton, P.; Casteilla, L.; Bourin, P.; Blancher, A.,	322
	Human fibroblasts share immunosuppressive properties with bone marrow mesenchymal stem cells. <i>J Clin Immunol</i> 2010 ,	323
	30, (4), 607-19.	324

24.	Youssef, A.; Aboalola, D.; Han, V. K., The Roles of Insulin-Like Growth Factors in Mesenchymal Stem Cell Niche. Stem Cells	325
	Int 2017 , 2017, 9453108.	326
25.	Koch, H.; Jadlowiec, J. A.; Campbell, P. G., Insulin-like growth factor-I induces early osteoblast gene expression in human	327
	mesenchymal stem cells. Stem Cells Dev 2005, 14, (6), 621-31.	328
26.	Toyama-Sorimachi, N.; Kitamura, F.; Habuchi, H.; Tobita, Y.; Kimata, K.; Miyasaka, M., Widespread expression of	329
	chondroitin sulfate-type serglycins with CD44 binding ability in hematopoietic cells. J Biol Chem 1997, 272, (42), 26714-9.	330
27.	Bae, S.; Ahn, J. H.; Park, C. W.; Son, H. K.; Kim, K. S.; Lim, N. K.; Jeon, C. J.; Kim, H., Gene and microRNA expression	331
	signatures of human mesenchymal stromal cells in comparison to fibroblasts. Cell Tissue Res 2009, 335, (3), 565-73.	332
28.	Kristensen, L. P.; Chen, L.; Nielsen, M. O.; Qanie, D. W.; Kratchmarova, I.; Kassem, M.; Andersen, J. S., Temporal profiling	333
	and pulsed SILAC labeling identify novel secreted proteins during ex vivo osteoblast differentiation of human stromal stem	334
	cells. Mol Cell Proteomics 2012, 11, (10), 989-1007.	335
29.	Kanawa, M.; Igarashi, A.; Ronald, V. S.; Higashi, Y.; Kurihara, H.; Sugiyama, M.; Saskianti, T.; Pan, H.; Kato, Y., Age-	336
	dependent decrease in the chondrogenic potential of human bone marrow mesenchymal stromal cells expanded with	337
	fibroblast growth factor-2. Cytotherapy 2013, 15, (9), 1062-72.	338
30.	Bessey, O. A.; Lowry, O. H.; Brock, M. J., A method for the rapid determination of alkaline phosphates with five cubic	339
	millimeters of serum. J Biol Chem 1946, 164, 321-9.	340
		341

Identification of Marker Genes for Predicting the Osteogenic Differentiation Potential of Mesenchymal Stromal Cells

ORIGINALITY REPORT 17% **INTERNET SOURCES PUBLICATIONS** SIMILARITY INDEX STUDENT PAPERS **PRIMARY SOURCES** Li, Kang, Jianxiang Liu, Mei Tian, Gang Gao, Xuesong Qi, Yan Pan, Jianlei Ruan, Chunxu Liu, and Xu Su. "CHMP4C Disruption Sensitizes the Human Lung Cancer Cells to Irradiation", International Journal of Molecular Sciences, 2015. **Publication** boris.unibe.ch 1 % Internet Source researchrepository.ucd.ie Internet Source bonndoc.ulb.uni-bonn.de Internet Source Maija Kiuru, Michelle A. Kriner, Samantha Wong, Guannan Zhu et al. "High-Plex Spatial RNA Profiling Reveals Cell Type-Specific Biomarker Expression during Melanoma Development", Journal of Investigative

Publication

Dermatology, 2021

6	Therapies", Springer Science and Business Media LLC, 2020 Publication	1 %
7	Kathryn L. Howe, Myron Cybulsky, Jason E. Fish. "The Endothelium as a Hub for Cellular Communication in Atherogenesis: Is There Directionality to the Message?", Frontiers in Cardiovascular Medicine, 2022 Publication	1%
8	journals.plos.org Internet Source	1%
9	mollus.oxfordjournals.org Internet Source	1%
10	stemcellres.biomedcentral.com Internet Source	1%
11	ouci.dntb.gov.ua Internet Source	<1%
12	Seemoon Yang, Changhee Lee. "Experimental Research on the Injection Rate of DME and Diesel Fuel in Common Rail Injection System by Using Bosch and Zeuch Methods", Energies, 2018 Publication	<1%
13	Yu-Hee Kim, Kyung-Ah Cho, Hyun-Ji Lee, Minhwa Park, Han Su Kim, Joo-Won Park, So-	<1%

Youn Woo, Kyung-Ha Ryu. "Identification of WNT16 as a Predictable Biomarker for Accelerated Osteogenic Differentiation of Tonsil-Derived Mesenchymal Stem Cells ", Stem Cells International, 2019

Publication

- "Stem Cells Heterogeneity Novel Concepts",
 Springer Science and Business Media LLC,
 2019
 Publication
- <1%
- Minyong Kang, Chang Wook Jeong, Choel Kwak, Hyeon Hoe Kim, Ja Hyeon Ku.
 "Preoperative neutrophil-lymphocyte ratio can significantly predict mortality outcomes in patients with non-muscle invasive bladder cancer undergoing transurethral resection of bladder tumor", Oncotarget, 2016

<1%

Publication

epublications.uef.fi

<1%

www.freepatentsonline.com

<1%

18 www.frontiersin.org


<1%

atvb.ahajournals.org

<1%

20	Internet Source	<1%
21	ebin.pub Internet Source	<1%
22	www.thno.org Internet Source	<1%
23	In Sook Kim. "In vitro response of primary human bone marrow stromal cells to recombinant human bone morphogenic protein-2 in the early and late stages of osteoblast differentiation", Embryologia, 06/2008 Publication	<1%
24	Ishii, M "Molecular markers distinguish bone marrow mesenchymal stem cells from fibroblasts", Biochemical and Biophysical Research Communications, 20050624 Publication	<1%
25	joralres.com Internet Source	<1%
26	molecular-cancer.biomedcentral.com Internet Source	<1%
27	s3-eu-west-1.amazonaws.com Internet Source	<1%
28	www.ashg.org Internet Source	<1%

29	www.researchgate.net Internet Source	<1%
30	"Mesenchymal Stem Cell in Veterinary Sciences", Springer Science and Business Media LLC, 2020 Publication	<1 %
31	Andrey Morgulis, Konstantin Ilin. "Indirect Taxis on a Fluctuating Environment", Mathematics, 2020 Publication	<1%
32	doi.org Internet Source	<1%
33	etheses.whiterose.ac.uk Internet Source	<1%
34	opus.bibliothek.uni-wuerzburg.de Internet Source	<1%
35	silo.pub Internet Source	<1%
36	www.researchsquare.com Internet Source	<1%
37	www.wjgnet.com Internet Source	<1%
38	"Cell Biology and Translational Medicine, Volume 4", Springer Science and Business Media LLC, 2018 Publication	<1%



45	eprints.soton.ac.uk Internet Source	<1%
46	www.nature.com Internet Source	<1%
47	Hiroshi Egusa. "Downregulation of Extracellular Matrix-Related Gene Clusters during Osteogenic Differentiation of Human Bone Marrow- and Adipose Tissue-Derived Stromal Cells", Tissue Engineering, 10/2007	<1%
48	Mesenchymal Stromal Cells, 2013. Publication	<1%
49	Perinatal Stem Cells, 2014. Publication	<1%
50	Yi Huang, Dan-Yang Ge, Hui Zong, Ju-Xin Yin, Xiao-Nan Qu, Shao-Wu Lv. "Active Site Mimicry of Glutathione Peroxidase by Glutathione Imprinted Selenium-Containing	<1%
	Trypsin", Catalysts, 2017	

integrated bioinformatics analyses", Cold Spring Harbor Laboratory, 2020

Publication

52

Chuiqin Fan, Maochuan Liao, Lichun Xie, Liangping Huang et al. "Single-Cell Transcriptome Integration Analysis Reveals the Correlation Between Mesenchymal Stromal Cells and Fibroblasts", Frontiers in Genetics, 2022

<1%

Publication

53

Hao ZHANG, Zhong-Li Ll, Xiang-Zheng SU, Li DING, Ji Ll, Heng ZHU. "Subchondral bone derived mesenchymal stem cells display enhanced osteo-chondrogenic differentiation, self-renewal and proliferation potentials", Experimental Animals, 2018

<1%

Publication

54

M. E. Bernardo, J. A. M. Emons, M. Karperien, A. J. Nauta et al. "Human Mesenchymal Stem Cells Derived from Bone Marrow Display a Better Chondrogenic Differentiation Compared with Other Sources", Connective Tissue Research, 2009

<1%

Publication

Exclude quotes

Identification of Marker Genes for Predicting the Osteogenic Differentiation Potential of Mesenchymal Stromal Cells

	J
GRADEMARK REPORT	
FINAL GRADE	GENERAL COMMENTS
/100	Instructor
PAGE 1	
PAGE 2	
PAGE 3	
PAGE 4	
PAGE 5	
PAGE 6	
PAGE 7	
PAGE 8	
PAGE 9	
PAGE 10	
PAGE 11	
PAGE 12	